Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2306 • ACR Convergence 2025
Prevalence and Clinical Significance of the Gastrointestinal Fat Halo Sign in Patients with Psoriatic Arthritis: A Cross-Sectional Study
Amir Haddad¹, Kathrien Mousa¹, Kateryna Milman¹, Najwan Nassrallah¹, Devy Zisman² and Sharbell Hashoul³, ¹Carmel Medical Centre, Haifa, Israel, ²Carmel Medical Center, Haifa, Israel, ³The Faculty of Humanities and Social Sciences. Uno Academic College, Haifa, Israel
Background/Purpose: The existence of a gut-joint axis is widely described in spondyloarthritis, linking intestinal dysbiosis, subclinical gut inflammation, and arthritis. The fat halo sign is…
Abstract Number: 1714 • ACR Convergence 2025
The perimenopause period is associated with increased levels of disease activity in psoriatic arthritis
Lihi Eder¹, Xianwei Li², Sahil Koppikar³, Iliana Lega⁴, Dafna D. Gladman⁵, Vinod Chandran¹ and Richard Cook⁶, ¹University of Toronto, Toronto, ON, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Canada, ³Women's College Hospital & University of Toronto, Markham, ON, Canada, ⁴University of Toronto and Women’s College Hospital, Toronto, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶University of Waterloo, Waterloo, Canada
Background/Purpose: Perimenopause is associated with a wide spectrum of symptoms, including mood changes, sleep disturbances, and joint pains. Limited information exists on the effect of…
Abstract Number: 1448 • ACR Convergence 2025
Influence of Sex on the Therapeutic Persistence of Guselkumab in Psoriatic Disease: a Retrospective National Cohort Study
Laure Gossec¹, Pascal Claudepierre², Arnaud Constantin³, Denis Jullien⁴, Samira Chaalal⁵, Julie Baraut⁵, Laure Cipiere⁵, Laurène Gautier⁶, Pierre Lemire⁷ and Thierry Passeron⁸, ¹Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ²Department of Rheumatology, CHU Henri Mondor, AP-HP, Créteil, France, Creteil, France, ³Department of Rheumatology, Toulouse University Hospital, Toulouse University and INSERM U¹²⁹¹, France, Toulouse, France, ⁴Hospices Civils de Lyon, Hôpital E. Herriot Department of Dermatologie, Lyon F-⁶⁹⁰⁰³ ; CIRI, Centre International de Recherche en Infectiologie, Team EIA : Epidermal immunity & Allergy, INSERM, U¹¹¹¹; Univ Lyon; Université de Lyon ¹; Ecole Normale Supérieure de Lyon; CNRS, UMR ⁵³⁰⁸, Lyon, France., Lyon, France, ⁵Johnson & Johnson, Issy les moulineaux, France, ⁶Johnson & Johson, Issy les Moulineaux, France, ⁷IQVIA, Real World Solutions, Paris, France, Paris, France, ⁸Johnson & Johnson, Nice, France
Background/Purpose: Psoriatic disease, including psoriasis (Pso) and psoriatic arthritis (PsA), seems to affect male and female patients differently in clinical presentation, disease progression and advanced…
Abstract Number: 1352 • ACR Convergence 2025
Prediction of 5-Year Fracture Risk in Rheumatoid and Psoriatic Arthritis Using REMS Technology
Marco Di Paola¹, Edmund J MacLaughlin², Kathleen Methric³, Maurizio Muratore⁴, Gianmarco Del Vecchio⁵, Giusy Peluso⁶, Ernesto Casciaro¹, Fabiola Rosa Contaldo⁷, Fiorella Anna Lombardi¹, Paola Pisani¹, Francesco Conversano¹ and Sergio Casciaro¹, ¹Institute of Clinical Physiology, National Research Council, Lecce, Puglia, Italy, ²Rheumatology Associates of Delmarva and BoneVue Diagnostics, Easton, MD, ³BoneVue Diagnostics, Catonsville, MD, ⁴ASL- LE, "Vito Fazzi" Hospital, Lecce, Puglia, Italy, ⁵Department of Research and Development, Echolight S.p.a., Lecce, Puglia, Italy, ⁶Department of Innovative Engineering, University of Salento, Lecce, Puglia, Italy, ⁷Department of Biological and Environmental Sciences and Technologies, University of Salento, University of Salento, Lecce, Puglia, Italy
Background/Purpose: Autoimmune arthritis, including Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PA), are among the most common forms of inflammatory joint diseases. These conditions affect joints…
Abstract Number: 0578 • ACR Convergence 2025
Real-world Effectiveness of Upadacitinib on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Core Domains for Patients with Psoriatic Arthritis: Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Philip J. Mease¹, Xiaolan Ye², Christopher Saffore³, Thomas Iyile⁴, Nicole Middaugh⁵, Taylor Blachley⁵, Melissa Eliot⁵ and Alexis Ogdie⁶, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²AbbVie Inc., Mettawa, IL, ³AbbVie Inc., waukegan, IL, ⁴AbbVie Inc, North Chicago, IL, ⁵CorEvitas, LLC, Waltham, MA, ⁶Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE
Background/Purpose: Psoriatic arthritis (PsA) is a heterogenous inflammatory disease that can cause substantial impairment in quality of life in affected patients. The Group for Research…
Abstract Number: 0552 • ACR Convergence 2025
Radiographic Sacroiliitis Progression in Psoriatic Arthritis
Virginia Carrizo Abarza¹, Pankti Mehta², Fadi Kharouf³, Shangyi Gao⁴, Dafna D. Gladman⁵, Vinod Chandran⁶ and Denis Poddubnyy⁷, ¹Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ²University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ³University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁴Gladman-Krembil Psoriatic Arthritis Research Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: Radiographic sacroiliitis is an important indicator of axial involvement psoriatic arthritis (PsA), but only little is known about factors associated with progression of sacroiliitis.…
Abstract Number: 0527 • ACR Convergence 2025
Gaps In Documentation Of Psoriatic Arthritis Domains In General Rheumatologic Practices Compared To Rheumatology-Dermatology Combined Clinics
Alexandra Lauren Rice¹, Sarah Hopkins Gillespie², Nikhil Sai³, Soumya Reddy¹, Joseph Merola⁴, Rebecca Haberman⁵, Alexis Ogdie⁶ and Jose Scher⁷, ¹NYU Grossman School of Medicine, New York, NY, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁴UT Southwestern Medical Center, Dallas, TX, ⁵NYU Langone Health, New York, NY, ⁶Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ⁷New York University School of Medicine, New York, NY
Background/Purpose: To apply current treatment recommendations for psoriatic arthritis (PsA), clinicians must perform a comprehensive assessment of psoriatic disease domains, including a musculoskeletal exam (tender…
Abstract Number: 0110 • ACR Convergence 2025
SKG Mice Develop CD4⁺ T Cell–Driven Psoriasis and Enable Study of Endogenous Antigen-Specific Responses
Yuka Nakao¹, Astha Patel¹, Bahram Razani², Steven yu¹, Steven Lazarevsky², Marlys Fassett² and Judith Ashouri¹, ¹University of California, San Francisco, San Francisco, CA, ²UCSF Department of Dermatology, San Francisco, CA
Background/Purpose: Psoriasis (Pso) and psoriatic arthritis (PsA) are chronic immune-mediated diseases affecting millions, yet early immunologic triggers remain poorly defined. Therapies targeting TNFα, IL-17, and…
Abstract Number: 0580 • ACR Convergence 2025
Persistence and Disease Activity Control among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy
Philip J. Mease¹, Nicole Middaugh², Yolanda Muñoz Maldonado², Chao Song³, Melissa Eliot², Robert Low³ and Alexis Ogdie⁴, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²CorEvitas, LLC, Waltham, MA, ³UCB, Smyrna, GA, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) is a chronic disease that causes inflammation of the joints, entheses, spine, skin, and nails.1 While available advanced treatments (txs) for…
Abstract Number: 2370 • ACR Convergence 2025
Comparative Efficacy and Safety of IL-17 Inhibitors Versus Adalimumab in Biologic-Naive Psoriatic Arthritis Patients: A Meta-Analysis of Randomized Controlled Trials
Punith Chirumamilla¹, Ravi Medarametla², Anjani Mahesh Kumar Cherukuri³, Sri Laxmi Priya Sunkara⁴, Pranathi Bandarupalli⁵, Rithish Nimmagadda⁶, Greeshma Erasani⁷, Pavana Sakhamuri⁸ and Stephen Lindsey⁹, ¹Baptist Memorial Hospital North Mississippi, Oxford, MS, ²Mamata Medical College, Guntur, Andhra Pradesh, India, ³Guntur Medical College, Guntur, Andhra Pradesh, India, ⁴White river medical center, batesville, AR, ⁵Mercy St Vincent Medical Center, Toledo, OH, ⁶One Brooklyn Health, New York, NY, ⁷University of Missouri-Kansas city school of medicine, KCMO, MO, ⁸LSUHSC, Lafayette, LA, ⁹LSU Health Sciences Center-New Orleans, Baton Rouge, LA
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated disease which involves joints, skin, and nails, leading to deformities, decreased function, lower quality of life, and…
Abstract Number: 2341 • ACR Convergence 2025
Bimekizumab Treatment Resulted in Long-Term Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire in Patients with Active Psoriatic Arthritis: Up to 3-Year Results from Two Phase 3 Studies
Ana-Maria Orbai¹, Dafna D. Gladman², Laura Coates³, Maarten de Wit⁴, Barbara Ink⁵, Rajan Bajracharya⁵, Patrick Healy⁶, Jérémy Lambert⁷ and Laure Gossec⁸, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ³Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁴Patient Research Partner, Stichting Tools, Amsterdam, Netherlands, ⁵UCB, Slough, England, United Kingdom, ⁶UCB, Morrisville, NC, ⁷UCB, Colombes, France, ⁸Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. The PsA Impact of Disease-12 (PsAID-12) questionnaire is…
Abstract Number: 2305 • ACR Convergence 2025
Predictors of Hospitalization and Emergency Department Visits Among Patients with Psoriatic Disease: Insights from the Forward Psoriasis Registry
Alexis Ogdie¹, Ellen Romich², Brian Coburn³, Rebecca Schumacher⁴ and Kaleb Michaud⁵, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ²University of Pennsylvania, Media, PA, ³Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ⁵University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with psoriasis and psoriatic arthritis (PsA) are at increased risk for metabolic comorbidities and poorer long-term outcomes compared to the general population. Identifying…
Abstract Number: 1713 • ACR Convergence 2025
Diagnostic Delay in Psoriatic Arthritis and its Impact on Radiological Outcomes: A Systematic Review and Meta-analysis of 23,894 Patients
Mohamed Abdelsalam¹, Menat Alla Ayman Ali Mahdy², Maryam Lasheen³, Hadeer Hafez⁴, Nourhan Abouelella⁵, Abdelhfeez Moshrif⁶ and Mohamed Reda Awad⁷, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ³Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ⁴⁶th October University, ⁶ october, Al Jizah, Egypt, ⁵Faculty of Medicine, Misr University for Science and Technology, ⁶ october, Al Jizah, Egypt, ⁶Al Azhar University, Asyut, Egypt, assyut, Asyut, Egypt, ⁷Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt
Background/Purpose: Psoriatic arthritis (PsA) remains widely underdiagnosed and misdiagnosed worldwide, leading to delays in appropriate management and increased disease burden. While diagnostic delay has been…
Abstract Number: 1447 • ACR Convergence 2025
Long-term impact of secukinumab on the prevention of psoriatic arthritis in patients with psoriasis: a 5-year pooled analysis of the ERASURE, FIXTURE and SCULPTURE studies
Ulrich Mrowietz¹, Laura Coates², Diamant Thaçi³, Mark Lebwohl⁴, Bardur Sigurgeirsson⁵, Richard B. Warren⁶, Richard G. Langley⁷, Andreas Clemens⁸, Cynthia Vizcaya⁸, Weibin Bao⁹, Kim Hoyt¹⁰, Lara Gómez¹¹ and Robert Bissonnette¹², ¹Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ³Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁴Icahn School of Medicine at Mount Sinai, New York, NY, ⁵University of Iceland, Faculty of Medicine, Department of Dermatology,, Reykjavik, Iceland, ⁶Dermatology Centre, Northern Care Alliance, NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ⁷Dalhousie University, Halifax, NS, Canada, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Novartis Farmaceutica, Madrid, Spain, ¹²Innovaderm, Montreal, Québec, Canada
Background/Purpose: Secukinumab is a fully human monoclonal antibody that selectively inhibits interleukin-17A, demonstrating robust and sustained efficacy in moderate to severe psoriasis (PsO) and psoriatic…
Abstract Number: 1303 • ACR Convergence 2025
Impact of Fruits and Vegetables Intake on Immune-mediated Inflammatory Diseases：a Two-sample Mendelian Randomization Study
Xuemei Tang, Yuting Zhou, Yuxiao Chen, Xinglin Wu and Qiang Luo, Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Chongqing, China, Chongqing, China (People's Republic)
Background/Purpose: A balanced diet can prevent diseases and promote physical and mental health. Accumulating evidence shows that fruits and vegetables (F&Vs) intake is associated with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].